Email

haohu@um.edu.mo

Tel

+853 8822 8538

Office

E12-1050

Consultation Hours

Mon 15:00-16:00
Tue 15:00-16:00

Hao HU 胡豪

Professor, Institute of Chinese Medical Sciences

Academic Qualifications

  • Postdoctoral, University of Montreal
  • Ph.D, Sichuan University
  • M.A, Sichuan University
  • B.A, Harbin Engineering University

Teaching

HSCI4010Pharmaceutical Economics and PolicyUndergraduate courses
CMED7005International Business and Law for MedicineM.Sc. Course
CMED7029Research MethodologyM.Sc. Course
CMED7032Health Industry InnovationM.Sc. Course
CMED7034Application Methodology for Medicinal ManagementM.Sc. Course
HSCI7008Health Systems and PolicyM.Sc. Course
CMED8011Advances in Medicinal AdministrationPh.D. Course

Research

  • Disease Modeling and Simulation
  • Health System Modeling
  • Pharmacoepidemiology and Pharmacoeconomics

  1. Zou H, Xue Y, Chen X, Lai Y, Yao D, Ung COL, Hu H*. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma. PLOS ONE. 2023; 18(10): e0292239.
  2. Xue Y, Zou H, Ruan Z, Chen X, Lai Y, Yao D, Ung COL*, Hu H*. Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. Frontiers in Endocrinology. 2023;14:1254398.
  3. Chen X, Shi J, Lai Y, Xue Y, Ung COL*, Hu H*. Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design. Chinese Medicine. 2023;18:58.
  4. Ruan Z, Jiang Y, Shi H, Jia R, Ung COL, Hu H*. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. Expert Review of Clinical Pharmacology. 2023; 16(2): 161-176.
  5. Xue Y, Ruan Z, Ung, COL, Lai Y, & Hu H*. Policy analysis of system responses to addressing and reversing the obesity trend in China: a documentary research. BMC Public Health. 2023; 23(1): 1198.
  6. Yan X, Zou H, Lai Y, Ung CO, Hu H*. Efficacy and safety of first-line targeted treatment and immunotherapy for patients with biliary tract cancer: a systematic review and meta-analysis. Cancers. 2023;15(1):39.
  7. Zou H, Lei Q, Yan X, Lai Y, Ung CO, Hu H*. Clinical outcomes associated with monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for advanced hepatocellular carcinoma in real-world practice: a systematic literature review and meta-analysis. Cancers. 2023;15(1):260.
  8. Lei Q, Yan X, Zou H, Jiang Y, Lai Y, Ung CO, Hu H*. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Discover Oncology. 2022;13(1):95.
  9. Hu H*, Su J, Ma J. Smart hospital innovation: technology, service, and policy. Frontiers in Public Health. 2022;10:845577.
  10. Lai Y, Wang R, Li W, Zhu H, Fei S, Shi H, Lu N, Ung COL, Hu H*, Han S*. Clinical and economic analysis of Gastrodin injection for dizziness or vertigo: a retrospective cohort study based on electronic health records in China. Chinese Medicine. 2022;17: 6.
  11. Lin Q, Xue Y, Zou H, Ruan Z, Ung CO, Hu H*. Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology. 2022;15(12):1461-9.
  12. Liu L, Ruan Z, Ung CO, Zhang Y, Shen Y, Han S, Jia R, Qiao J, Hu H*, Guo L*. Long-term cost-effectiveness of subcutaneous once-weekly semaglutide versus polyethylene glycol loxenatide for treatment of type 2 diabetes mellitus in China. Diabetes Therapy. 2022; 14(1):93-107.
  13. Ruan Z, Zou H, Lei Q, Ung COL, Shi H, Hu H*. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(4): 555-574.
  14. Ruan Z, Ung CO, Shen Y, Zhang Y, Wang W, Luo J, Zou H, Xue Y, Wang Y, Hu H*, Guo L*. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China. Diabetes Therapy. 2022; 13:1737-1753.
  15. Xia C, Yao D, Lai Y, Xue Y, Hu H*. Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems. Chinese Medicine. 2022;17:5.
  16. Zou H, Ge Y, Lei Q, Ung CO, Ruan Z, Lai Y, Yao D, Hu H*. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. Hepatology International. 2022; 16:27–37.
  17. Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung COL*, Hu H*. Economic burden and quality of life of hepatocellular carcinoma in greater China: a systematic review. Frontiers in Public Health. 2022;21:767.
  18. Lai Y, Chen S, Li M, Ung CO, Hu H*. Policy interventions, development trends, and service innovations of internet hospitals in China: documentary analysis and qualitative interview study. Journal of Medical Internet Research. 2021;23(7): e22330.
  19. Li M, Cheng K, Ku K, Li J, Hu H*, Ung CO*. Factors influencing the length of hospital stay among patients with chronic obstructive pulmonary disease (COPD) in macao population: a retrospective study of inpatient health record. International Journal of Chronic Obstructive Pulmonary Disease. 2021;16:1677.
  20. Li M, Chen S, Lai Y, Liang Z, Wang J, Shi J, Lin H, Yao D, Hu H*, Ung CO*. Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the US, EU, and China using a logic model. Frontiers in Medicine. 2021; 8:778.
  21. Li M, Chen S, Zhao H, Tang C, Lai Y, Ung CO, Su J*, Hu H*. The short-term associations of chronic obstructive pulmonary disease hospitalizations with meteorological factors and air pollutants in Southwest China: a time-series study. Scientific Reports. 2021;11:12914.
  22. Ruan Z, Yang L, Shi H, Yue X, Wang Y, Liang M, Hu H*. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 diabetes: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research. 2021, 21(2):221-233.
  23. Salem A, Zhong H, Ramos M, Lamotte M, Hu H*. Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China. BMJ open. 2021;11(4):e043664.
  24. Shi H, Chen X, Liu X, Zhu H, Yu F, Ung CO, Chan WS, Hu H*, Han S*. National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018. Journal of Pharmaceutical Policy and Practice. 2021; 14:45.

  1. Leung SW, Hu H. 2016. Evidence-based Research Methods for Chinese Medicine. Springer.
  2. 胡豪, 张黎明. 2014. 重塑价值逻辑：中国制药产业的业务模式创新. 北京: 清华大学出版社. (Hu H, Zhang LM. 2014. Rebuild Value Logics: Business Model Innovation in the Chinese Pharmaceutical Industry. Beijing: Tsinghua University Press. (In Chinese))